Syncona Share Chat (SYNC)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Syncona	LSE:SYNC	London	Ordinary Share	GG00B8P59C08	ORD NPV

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-8.00p	-2.95%	263.50p	264.00p	265.00p	271.50p	264.00p	271.50p	244,075	16:35:17

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Equity Investment Instruments	28.7	5.1	0.8	337.8	1,742.32

Syncona Share Discussion Threads

Showing 18476 to 18500 of 18500 messages

Chat Pages: 740 739 738 737 736 735 734 733 732 731 730 729 Older

Date	Subject	Author	Discuss
13/12/2018 09:34	Just a bit more about potential from Blue Earth website “Fluciclovine F 18 is an artificial amino acid that has been labelled with F 18 to allow positron emission tomography (PET) imaging. Fluciclovine F 18 appears to be avidly taken up by a number of cancer cell types, including prostate cancer and glioma (a type of brain tumour). Blue Earth Diagnostics is investigating fluciclovine F 18 as a molecular diagnostic imaging agent for various cancers. It has been evaluated most extensively for disease localisation and detection in prostate cancer patients with suspected biochemical recurrence following earlier treatment. Prostate Cancer Blue Earth Diagnostics’ first product, Axumin™ (fluciclovine F 18), was approved by the U.S. Food & Drug Administration (FDA) in May 2016 for use in PET imaging of biochemically recurrent prostate cancer. In May 2017, the European Medicines Agency (EMA) granted marketing authorisation for Axumin use in PET imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment. Blue Earth Diagnostics filed for marketing approval for Axumin with both the FDA and the EMA based on studies conducted on over 800 subjects in the USA, Italy and Norway. In May 2018, Blue Earth Diagnostics expanded its prostate cancer portfolio through the acquisition of exclusive, worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. Glioma Blue Earth Diagnostics has obtained Orphan Drug Designation (ODD) from the FDA and the EMA for the use of fluciclovine F 18 in the diagnosis of glioma, a form of brain cancer. Gliomas make up about 30% of all brain and central nervous system tumours and 80% of all malignant brain tumours. The symptoms, prognosis, and treatment of a malignant glioma depend on the person’s age, the exact type of tumour, and the location of the tumour – which often penetrates deep into the brain. Blue Earth Diagnostics plans to investigate the role of fluciclovine F 18 PET imaging in evaluating the spread of both high and low grade glioma within the brains of affected patients. Other diseases The company anticipates the development of follow-on indications for fluciclovine 18 in the diagnosis of other tumour types, as well as other applications in prostate cancer.	brexitplus	Read Full Thread Reply
12/12/2018 19:39	Axumin( Blue Earth) now available in France	ltinvestor	Read Full Thread Reply
12/12/2018 11:25	Lux Yes, more great news today. I’ve contacted Syncona to ask if they will be issuing their usual RNSs about the two releases. It appears the Blue Earth news, according to Syncona, only justifies going out via their email to investors. So sign up today!!!	brexitplus	Read Full Thread Reply
12/12/2018 11:15	Blue Earth on a roll by the sounds of it hxxp://www.blueearthdiagnostics.com/first-production-and-administration-of-axumin-fluciclovine-18f-in-france/ First patients commercially dosed in France (for prostate). Update: "Axumin is commercially available in France, Norway, the Czech Republic, The Netherlands, United Kingdom and Austria with further European countries set to follow soon."	luxaeterna1	Read Full Thread Reply
12/12/2018 07:01	This is new news, following publication of test results on 19th November. Well spotted. I’m surprised Syncona didn’t release an RNS.	brexitplus	Read Full Thread Reply
11/12/2018 14:05	hxxps://www.synconaltd.com/investors/news/blue-earth-diagnostics-announces-us-food-and-drug-administration-fda-filing-acceptance-of-supplemental-new-drug-application-snda-for-18f-fluciclovine-pet-imaging-in-glioma/?accept_disclaimer=true it appears that Blue Earth have sent Axumin phase 3 trial data to the FDA for a second condition, ie cancerous brain gliomas. I am not 100% clear if this is major news or just ongoing pr.	luxaeterna1	Read Full Thread Reply
06/12/2018 16:35	Autolus doing well despite the US falls.	brexitplus	Read Full Thread Reply
21/11/2018 18:50	https://www.proactiveinvestors.co.uk/companies/news/209677/nightstar-therapeutics-deserves-a-spot-on-your-watchlist-if-you-are-an-aggressive-biotech-investor-209677.html	ltinvestor	Read Full Thread Reply
21/11/2018 18:18	Results presentation: httPs://www.synconaltd.com/media/1316/syncona-interim-presentation-201118-final.pdf and webcast available here: htTps://www.synconaltd.com/investors/results-centre/?accept_disclaimer=true	rambutan2	Read Full Thread Reply
21/11/2018 08:28	Syncona also made charitable donations of £4.7m during the last year.This, IMO, is an exceptional company...	ltinvestor	Read Full Thread Reply
21/11/2018 08:15	I wouldn’t be surprised if there is a lot of outside interest in Blue Earth. User numbers increasing quickly. Large newsflow in the past few months. Profitable.	brexitplus	Read Full Thread Reply
21/11/2018 08:01	Very good numbers! Happy days. DL	davidlloyd	Read Full Thread Reply
21/11/2018 07:32	As I said over a year ago when the share price was around £1.70.Buy,sit back and watch the growth....Blue Earth diagnostics very undervalued in the accounts...	ltinvestor	Read Full Thread Reply
21/11/2018 07:28	Excellent interims.	brexitplus	Read Full Thread Reply
19/11/2018 14:59	Autolus share price all over the place recently but looks like an upward trend. Nightstar a bit variable.	brexitplus	Read Full Thread Reply
13/11/2018 07:25	Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company, Nightstar Therapeutics Plc (NASDAQ: NITE) (Nightstar), has announced the initiation of its Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and has reported Third Quarter 2018 Financial Results. The announcement can be accessed on Nightstar's investor website at hxxp://ir.nightstartx.com	brexitplus	Read Full Thread Reply
10/11/2018 16:21	Nightstar up $2.5 in 3 days and presenting this coming week in London and two weeks later in New York.Presently $12.5 and wouldn’t be surprised to see $18 by end Dec	ltinvestor	Read Full Thread Reply
10/11/2018 06:27	Autolus finished at $48 last night with a high of $53.	brexitplus	Read Full Thread Reply
09/11/2018 09:24	Autolus spike ~30% last night in the US - News? New investor?	luxaeterna1	Read Full Thread Reply
09/11/2018 08:01	Bought Nightstar at $10....raised $80m a few weeks ago at $18!!	ltinvestor	Read Full Thread Reply
07/11/2018 16:59	Yes...there are 15 types of cancers targeted on page 10.	luxaeterna1	Read Full Thread Reply
07/11/2018 15:10	Thanks Lux Impressive presentation. With so much going on its hard to keep up!!!	brexitplus	Read Full Thread Reply
07/11/2018 10:57	Thanks Brexitplus, I also noticed a September 2018 Autolus presentation on the Autolus page hTtps://www.autolus.com/investor-relations/news-events/presentations	luxaeterna1	Read Full Thread Reply
02/11/2018 22:09	There is a Syncona presentation at the Numis Mid-Cap Conference dated 31/10/2018 on the Syncona website.	brexitplus	Read Full Thread Reply
02/11/2018 11:08	hxxps://ash.confex.com/ash/2018/webprogram/Paper118050.html Apparently the text overview of the Freeline paper on Haemophilia. Can't think how these two trials could have gone any better "Results: As of 26 June 2018, two patients had been treated with FLT180a at the low dose of 4.5 x 1011 vg/kg and observed for 20 and 14 weeks, respectively. Within 4 weeks of receiving a single infusion of FLT180a, both patients achieved FIX levels of >30%, which is well within the mild haemophilia range where the risk of spontaneous bleeding is absent and bleeding occurs only after major surgery or injury. Patients 1 and 2 had peak FIX expression around Week 12 with levels of 48% and 66%, respectively. After the discontinuation of prophylactic steroids FIX levels stabilised at 46% and 48%, respectively. No serious adverse events have been reported and there has not been any significant increase in liver enzymes. Prophylaxis with exogenous coagulation factor was stopped within the first week post FLT180a administration due to sufficient rise in patients endogenous FIX. Neither patient has required exogenous coagulation factor after this first week. No spontaneous bleeds have occurred. A traumatic bleed was reported by Patient 1 (right middle finger cut) at Week 10 but did not require treatment with FIX concentrates. The patient’s FIX activity at the time was 38%."	luxaeterna1	Read Full Thread Reply

Chat Pages: 740 739 738 737 736 735 734 733 732 731 730 729 Older